We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
DaVita Inc (DVA) is a leading medical care facilities business with stocks listed in the US. It opened the day at US$122.25 after a previous close of US$121.8. During the day the price has varied from a low of USD121.31 to a high of USD122.81. The latest price was USD122.27 (25 minute delay). DaVita is listed on the NYSE. All prices are listed in US Dollars.
How to buy shares in DaVita
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for DaVita. Find the share by name or ticker symbol: DVA. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until DaVita reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$120.28, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of DaVita, depending on your broker.
- Check in on your investment. Congratulations, you own a part of DaVita. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
What's in this guide?
- DaVita key stats
- Compare share trading platforms
- Is DaVita stock a buy or sell?
- DaVita performance over time
- Can I short DaVita shares?
- Is DaVita suitable for ethical investing?
- Are DaVita shares over-valued?
- DaVita's financials
- How volatile are DaVita shares?
- Does DaVita pay a dividend?
- Have DaVita shares ever split?
- Other common questions
DaVita share priceUse our graph to track the performance of DVA stocks over time.
DaVita shares at a glance
|52-week range||US$75.3 - US$129.59|
|50-day moving average||US$120.3443|
|200-day moving average||US$113.4213|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||US$6.469|
Compare share trading platforms to buy stock
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Is it a good time to buy DaVita stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
DaVita price performance over time
|1 month (2021-05-13)||-2.91%|
|3 months (2021-03-12)||12.75%|
|6 months (2020-12-11)||12.88%|
|1 year (2020-06-12)||56.26%|
|2 years (2019-06-13)||149.38%|
|3 years (2018-06-13)||72.28%|
|5 years (2016-06-13)||61.82%|
Is DaVita under- or over-valued?
Valuing DaVita stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of DaVita's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
DaVita's P/E ratio
DaVita's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 19x. In other words, DaVita shares trade at around 19x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
DaVita's PEG ratio
DaVita's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.9621. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into DaVita's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
DaVita's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$2.3 billion.
The EBITDA is a measure of a DaVita's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||US$11.5 billion|
|Operating margin TTM||14.8%|
|Gross profit TTM||US$3.6 billion|
|Return on assets TTM||6.05%|
|Return on equity TTM||33.14%|
|Market capitalisation||US$12.9 billion|
TTM: trailing 12 months
Shorting DaVita shares
There are currently 2.6 million DaVita shares held short by investors – that's known as DaVita's "short interest". This figure is 2.8% down from 2.7 million last month.
There are a few different ways that this level of interest in shorting DaVita shares can be evaluated.
DaVita's "short interest ratio" (SIR)
DaVita's "short interest ratio" (SIR) is the quantity of DaVita shares currently shorted divided by the average quantity of DaVita shares traded daily (recently around 617220.3271028). DaVita's SIR currently stands at 4.28. In other words for every 100,000 DaVita shares traded daily on the market, roughly 4280 shares are currently held short.
However DaVita's short interest can also be evaluated against the total number of DaVita shares, or, against the total number of tradable DaVita shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case DaVita's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 DaVita shares in existence, roughly 20 shares are currently held short) or 0.0379% of the tradable shares (for every 100,000 tradable DaVita shares, roughly 38 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against DaVita.
Find out more about how you can short DaVita stock.
DaVita's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like DaVita.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
DaVita's total ESG risk score
Total ESG risk: 20.07
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and DaVita's overall score of 20.07 (as at 12/31/2018) is pretty good – landing it in it in the 24th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like DaVita is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
DaVita's environmental score
Environmental score: 2.6/100
DaVita's environmental score of 2.6 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that DaVita is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
DaVita's social score
Social score: 10.68/100
DaVita's social score of 10.68 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that DaVita is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
DaVita's governance score
Governance score: 7.8/100
DaVita's governance score puts it squarely in the 3rd percentile of companies rated in the same sector. That could suggest that DaVita is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
DaVita's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. DaVita scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that DaVita has, for the most part, managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
|Total ESG score||20.07|
|Total ESG percentile||24.1|
|Environmental score percentile||3|
|Social score percentile||3|
|Governance score percentile||3|
|Level of controversy||2|
DaVita share dividends
We're not expecting DaVita to pay a dividend over the next 12 months.
Have DaVita's shares ever split?
DaVita's shares were split on a 2:1 basis on 8 September 2013. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your DaVita shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for DaVita shares which in turn could have impacted DaVita's share price.
DaVita share price volatility
Over the last 12 months, DaVita's shares have ranged in value from as little as US$75.3 up to US$129.59. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while DaVita's is 1.2902. This would suggest that DaVita's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services; vascular access services; clinical research programs; physician services; and comprehensive care services. As of December 31, 2020, it provided dialysis and administrative services in the United States through a network of 2,816 outpatient dialysis centers serving approximately 204,200 patients; and operated 321 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 36,700 patients. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
Frequently asked questions
Ask an Expert